ReNeuron Group (RENE) today signed a collaboration agreement with a US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.
This is in line with its efforts to advance its proprietary exosome technology platform as a delivery vehicle for drugs that would otherwise be unable to reach their site of action.
ReNeuron is to use its proprietary exosomes as well as its sequence-based know-how, while the US-based biopharmaceutical company will provide expertise in the field of synthetic oligonucleotides to optimise their loading into exosomes.
The initial feasibility stage collaboration will ideally find candidates with suitable pharmaceutical properties to evaluate pre-clinical safety and potential efficacy.
No cash payments are made between the parties at this stage, but if successful, a product cross-licensing agreement will be signed by the parties ahead of pre-clinical and clinical development of therapeutic candidates.
Shares in ReNeuron Group were up 7% following the announcement.
Olav Hellebø, Chief Executive Officer of ReNeuron, said: “We are delighted to be collaborating with a biopharmaceutical company that has considerable experience in the development of novel oligonucleotide-based therapeutics."
"Exosomes are biological nanoparticles ideally suited to the delivery of nucleic acid-based therapeutics due to their natural occurrence and abundance, their ability to protect their cargo from degradation and their potential for favourable bio-distribution.”
Follow News & Updates from ReNeuron here: